Items tagged with "NALTREXONE"


publications  |   Probation Clients’ Barriers to Access and Use of Opioid Use Disorder Medications

Published: July 2, 2019
Some probationers with opioid use disorders (OUDs) cannot access medications to treat their disorders—methadone, buprenorphine, and naltrexone—which have been FDA-approved and proven-effective. This article shared finding from a survey of 26 Illinois probation department directors on how probation departments respond to clients with OUDs, focusing on the barriers to accessing OUD medications. The article noted that a majority of probation department leaders perceived barriers for probation client access to OUD medications including lack of medical personnel experience, cost, need for guidance on medications, and regulations prohibiting medication use. The article highlighted a need for training, interagency collaboration, and policy changes to increase access to, education on, and use of, medications for probation clients. Such efforts may result in positive outcomes such as reduced recidivism, increased quality of life, and reduced mortality.



articles  |   Probation Clients’ Barriers to Access and Use of Opioid Use Disorder Medications

Published: June 17, 2019
Some individuals on probation who have opioid use disorders (OUDs) cannot access effective, FDA-approved medications-methadone, buprenorphine, and naltrexone-to treat their disorders. This article shared finding from a survey of 26 Illinois probation department directors on how probation departments respond to clients with OUDs, focusing on the barriers to accessing OUD medications. The article noted that a majority of probation department leaders perceived barriers for probation client access to OUD medications including lack of medical personnel experience, cost, need for guidance on medications, and regulations prohibiting medication use. The article highlighted a need for training, interagency collaboration, and policy changes to increase access to, education on, and use of, medications for probation clients. Such efforts may result in positive outcomes such as reduced recidivism, increased quality of life, and reduced mortality.



publications  |   An Overview of Medication- Assisted Treatment for Opioid Use Disorders for Criminal Justice-Involved Individuals

Published: July 24, 2017
There is a national opioid epidemic and one intervention to help those suffering from an opioid use disorder (OUD) is medication-assisted treatment (MAT). MAT is the use of medications in conjunction with behavioral therapy as part of a long-term treatment regimen. There are three main MAT medications used today—methadone, buprenorphine, and naltrexone. Research has shown MAT, in particular the use of methadone or buprenorphine, is considered an evidence-based practice to treat OUD. Studies indicate those in MAT have better outcomes than those who engage in therapy alone. This article provides an overview of MAT with a focus on use with criminal justice populations.



articles  |   An Overview of Medication-Assisted Treatment for Opioid Use Disorders for Criminal Justice-Involved Individuals

Published: July 18, 2017
There is a national opioid epidemic and one intervention to help those suffering from an opioid use disorder (OUD) is medication-assisted treatment (MAT). MAT is the use of medications in conjunction with behavioral therapy as part of a long-term treatment regimen. There are three main MAT medications used today—methadone, buprenorphine, and naltrexone. Research has shown MAT, in particular the use of methadone or buprenorphine, is considered an evidence-based practice to treat OUD. Studies indicate those in MAT have better outcomes than those who engage in therapy alone. This article provides an overview of MAT with a focus on use with criminal justice populations.